DiscoverResearch To Practice | Oncology VideosHR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

Update: 2025-10-13
Share

Description

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

  • Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00 )
  • Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18 )
  • Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10 )

CME information and select publications

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)

Dr. Neil Love